J&J

Every Closure Counts

J&J MedTech's (Ethicon's) advanced wound closure portfolio is built for every detail, every moment, and every specialty. Because every closure counts.

Proven SSI Risk Reduction

Ethicon Plus Antibacterial Sutures
Shop Now
J&J

The average additional cost of managing a single patient with an SSI is estimated at $28,21911,2

Plus Sutures were associated with up to a 29% reduction in the risk of surgical site infection in multiple recent meta-analyses3-6

Triclosan-coated sutures are supported by the highest level of clinical evidence (1A) and by health authorities around the world7-12*

Strong Microbial Barrier

DERMABOND™ PRINEO™ Skin Closure System
DERMABOND™ ADVANCED™ Skin Closure System
Shop Now
J&J

Strong, protected closure for optimal wound healing13-15

Provides a flexible microbial barrier with 99% protection in vitro for 72 hours against organisms commonly responsible for SSIs16

Over 25% reduction in length of stay with DERMABOND™ Adhesive17

Strength and Security

STRATAFIX™ Knotless Tissue Control Devices give surgeons consistent control over every pass and combine the strength and security of interrupted closure with the efficiency of continuous closure.18,19
STRATAFIX™ Spiral Knotless Tissue Control Device
STRATAFIX™ Symmetric Knotless Tissue Control Device
Shop Now

Adjunctive Hemostats

J&J MedTech is equipping surgical teams with world-class brands and breakthrough innovations to help lessen the impact and incidence rate of perioperative complications and accelerate the patient's healing journey.

The SURGICEL™ Family of Products

Our solution for continuous oozing is our SURGICEL™ Family of products. These products are associated with:20
  • Up to 25% less product usage
  • 38-52% lower transfusion costs
  • Up to 15% reduction in length of stay
SURGICEL™ Powder Absorbable Hemostat
SURGICEL SNoW™ Absorbable Hemostat
Shop Now
J&J

View our Hemostatis Optimization Program

View Now

References:

*CDC, WHO, ACS/SIS, NICE, and KRINKO guidelines on reducing the risk of surgical site infections are general to triclosan-coated sutures and are not specific to any one brand.

  1. Forrester JD, Maggio PM, Tennakoon L. Cost of Health Care-Associated Infections in the United States. J Patient Saf. 2022;18(2):e477-e479. doi:10.1097/PTS.0000000000000845
  2. Schweizer ML, Cullen JJ, Perencevich EN, Vaughan Sarrazin MS. Costs Associated With Surgical Site Infections in Veterans Affairs Hospitals. JAMA Surg. 2014 Jun;149(6):575-81. doi: 10.1001/jamasurg.2013.4663. PMID: 24848779; PMCID: PMC7393605.
  3. Miyoshi N, Fujino S; Clinical Study Group of Osaka University; Colorectal Cancer Treatment Group (CSGOCG). Triclosan-coated sutures to reduce surgical site infection in abdominal gastrointestinal surgery: A meta-analysis and systematic review. SurgOpen Sci. 2023 Sep 14;16:73-76.
  4. Edwards M, Graziadio S, Shore J, et al. Plus Sutures for preventing surgical site infection: a systematic review of clinical outcomes with economic and environmental models. BMC Surg. 2023 Oct 3;23(1):300.
  5. Suleiman AS, Abbass M, Hossain M, Choudhary P, Bhattacharya P, Islam MA. Impact of antibiotic-coated sutures on surgical site infections: a second-order meta-analysis. Int J Surg. 2024 Jan 1;110(1):507-519. doi:1097/JS9.0000000000000822. PMID: 37830948; PMCID: PMC10793740. https://journals.lww.com/international-journal-of-surgery/fulltext/2024/01000/impact_of_antibiotic_coated_sutures_on_surgical.51.aspx.
  6. Jalalzadeh
  7. De Jonge SW, Atema JJ, Solomkin JS, Boermeester MA. Meta-analysis and trial sequential analysis of triclosan-coated sutures for the prevention of surgical-site infection. Br J Surg. 2017;104(2):e118-e133.
  8. Berrios-Torres SI, Umscheid CA, Bratzler DW, et al. Centers for disease control and prevention guideline for the prevention of surgical site infection, 2017. JAMA Surg. 2017;152(8):784-791.
  9. Ban KA, Minei JP, Laronga C, et al. American college of surgeons and surgical infection society: surgical site infection guidelines, 2016 update. J Am Coll Surg. 2017; 224(1):59-74.
  10. NICE Guideline Updates Team (UK). Surgical site infection: prevention and treatment. NICE website. https:__www.nice.org.uk_guidance_ng125_chapter_Recommendations#closuremethods. Accessed April 3, 2020.
  11. World Health Organization. Global guidelines for the prevention of surgical site infection. https:__apps.who.int_iris_bitstream_handle_10665_250680_9789241549882-eng.pdf?sequence=8. Published November 2016. Accessed April 3, 2020.
  12. Prevention of postoperative wound infections. Recommendation of the Committee for Hospital Hygiene and Infection Prevention (KRINKO) at the Robert Koch Institute. Bundesgesundheitsbl. 2018;61(4):448-473.
  13. Su W. Study report for in vitro evaluation of microbial barrier properties of DERMABOND ProTape. 06TR071. December 4, 2006. Ethicon, Inc.
  14. es. AST-2012-0290. October 11, 2012. Ethicon, Inc.
  15. Kannon GA, Garrett AB. Moist wound healing with occlusive dressings. Dermatol Surg. 1995;21:583-590]
  16. Su W. Study report for in vitro evaluation of microbial barrier properties of DERMABOND ProTape. 06TR071. December 4, 2006. Ethicon, Inc
  17. Souza EC, FitaroniRB, JanuzelliDM, et al. Use of 2-octyl cyanoacryl ate for skin closure of sternal incisions in cardiac surgery: observations of microbial barrier effects. CurrMed Res Opin.2008;24(1):151-155
  18. Moran ME, Marsh C, Perrotti M. Bidirectional-barbed sutured knotless running anastomosis v classic Van Velthoven suturing in a model system. J Endourol. 2007;21(10):1175-1178.
  19. Vakil JJ, O’Reilly MP, Sutter EG, Mears SC, Belko SM, Khanuja HS. Knee arthrotomy repair with a continuous barbed suture: a biomechanical study. J Arthroplasty. 2011;26(5):710-713.
  20. Martyn D, Kocharian R, Lim S, et al. Reduction in hospital costs and resource consumption associated with the use of advanced topical hemostats during inpatient procedures. J Med Econ. 2015;18(6):474481.